Top Markets
Coin of the day
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.

Tibet Pharmaceuticals, Inc.

TBET
Rang în acțiuni #42421
Tibet Pharmaceuticals, Inc. operates as a specialized pharmaceutical company,... Tibet Pharmaceuticals, Inc. operates as a specialized pharmaceutical company, primarily focused on the research, development, manufacturing, marketing, and distribution of traditional Tibetan medicines. The company conducts its core activities through its operational subsidiary, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), which develops products within China to support the health of human respiratory, digestive, urinary, and reproductive systems. Among its currently commercialized products are: 25 Ingredients Mandrake Pill: Used for menstrual regulation and to address conditions like endometritis, pelvic inflammations, and anemia in women. 15 Ingredients Gentiana Pill: Prescribed for respiratory ailments including bronchitis, emphysema, asthma, and hoarseness. 28 Ingredients Pinang Pill: Aims to alleviate cold waist and hip pain, pus hematuria, and testicular swelling. 18 Ingredients Chebulic (Myrobalan) Frusemide Pill: Designed to treat various kidney issues, lower back and kidney pain, frequent or turbid urination, diabetes, and spermatorrhea. Pomegranate Nichirin Pill: Helps manage indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emissions. The company also maintains an active development pipeline. The Xuezang Guben pill is being developed for neurasthenia, insomnia, frequent urination, nocturnal emission, and menopausal symptoms. Shengke I is currently in Phase III clinical testing for type II diabetes, while Shengke II is in Phase II trials, exploring its potential for impotence, premature ejaculation, prostate disease, and memory loss. The Jiuzan pill, also a Phase II candidate, targets chronic gastroenteritis and peptic ulcers. Additionally, Antai pill is a pre-clinical stage product under investigation for hepatitis B. Tibet Pharmaceuticals further plans to commercialize Wupeng Pill, intended for a range of conditions including echinococcosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. Incorporated in 2009, the company was initially known as Shangri-La Tibetan Pharmaceuticals, Inc., before officially changing its name to Tibet Pharmaceuticals Inc. in July 2010. Its headquarters are located in Wanchai, Hong Kong.
Preț acțiune
$0.0001
Ultima sincronizare: 2025-12-30
Capitalizare de piață
$1.49K
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
HK
Tranzacționează Tibet Pharmaceuticals, Inc. (TBET)

Categorie

Prețul TBET cu capitalizarea de piață a B
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.
TBET
$0.0001
Capitalizarea de piață a Tibet Pharmaceuticals, Inc.(TBET)
Capitalizare de piață: $1.49K
În anul August 2026, Tibet Pharmaceuticals, Inc. are o capitalizare de piață de $1.49K. Acest lucru face ca Tibet Pharmaceuticals, Inc. să fie a 42421st-a cea mai valoroasă companie din lume, conform datelor noastre. Capitalizarea bursieră reprezintă valoarea totală de piață a acțiunilor în circulație ale unei companii listate și este utilizată frecvent pentru a măsura valoarea unei companii.
Istoricul capitalizării de piață a Tibet Pharmaceuticals, Inc. din 2023 până în 2026
TBET în comparație cu top 5 cele mai populare stocks
Prețul pentru TBET Activul B Capitalizarea de piață a B Rezultate
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.
$362,516 $1.49K
$5.383T +362,515,788,452.19%
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.
$297,871 $1.49K
$4.423T +297,871,461,431.18%
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.
$280,160 $1.49K
$4.160T +280,159,555,393.74%
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.
$246,688 $1.49K
$3.663T +246,688,271,751.85%
Tibet Pharmaceuticals, Inc. Tibet Pharmaceuticals, Inc.
$194,696 $1.49K
$2.891T +194,695,541,677.78%